March 16th 2025
Carl Schmid, executive director, HIV + Hepatitis Policy Institute, explains how a Supreme Court case could have far reaching implications for greater health screenings and preventative services beyond HIV and hepatitis.
Summarizing SGLT-2 Inhibitor Usage in People With Diabetes and HIV
January 16th 2025In persons living with HIV and diabetes, the management of diabetes is lagging behind the evidence. Despite SGLT-2 inhibitors demonstrating robust clinical data in the general population, they are grossly underused in persons with HIV and diabetes.
Read More
INSTIs and Cardiovascular Outcomes: More Complexity
October 28th 2024The significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.
Read More
Sexually Transmitted Infections (STI) Awareness Month: A Call for Education, Testing, and Prevention
April 2nd 2024April marks STI Awareness Month; guidelines decreasing the incidence of chlamydia and syphilis, future work needing to be done with regards to doxy-PEP, an increase in STIs during the pandemic, and more from this year by Contagion.
Read More
Increase in Incidence Rates of STIs in Adolescents During the COVID-19 Pandemic
February 18th 2024Investigators recently noted that despite a decrease in adolescent hospital visits during the height of the pandemic, there was an increase in sexually transmitted infections (STIs) in this population group.
Read More